Immunity to Melanoma Antigens: From Self-Tolerance to Immunotherapy

Advances in Immunology

Volumn 90, Issue , 2006, Pages 243-295

  Slingluff Jr , Craig L ^a   Chianese Bullock, Kimberly A ^a   Bullock, Timothy N J ^a   Grosh, William W ^a   Mullins, David W ^a   Nichols, Lisa ^a   Olson, Walter ^a   Petroni, Gina ^a   Smolkin, Mark ^a   Engelhard, Victor H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIGEN; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; INTERLEUKIN 2; MELAN A; MELANOMA ANTIGEN; MELANOMA HELPER PEPTIDE; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; PEPTIDE DERIVATIVE; PEPTIDE VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ABSENCE OF SIDE EFFECTS; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER CONTROL; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MELANOMA; MELANOMA CELL; MONOCYTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SENTINEL LYMPH NODE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNITY, CELLULAR; MELANOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF TOLERANCE; VACCINES, SUBUNIT;

EID: 33646244160     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2776(06)90007-8     Document Type: Review

References (162)

1. Alexander-Miller M.A., Leggatt G.R., and Berzofsky J.A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93 (1996) 4102-4107
2. Alexander-Miller M.A., Leggatt G.R., Sarin A., and Berzofsky J.A. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184 (1996) 485-492
3. Allan R.S., Smith C.M., Belz G.T., van Lint A.L., Wakim L.M., Heath W.R., and Carbone F.R. Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 301 (2003) 1925-1928
4. Altrich-VanLith M.L., Polefrone J.M., Ostankovitch M., Shabanowitz J., Hunt D.F., and Engelhard V.H. Deamidation and Amino Terminal Processing of a T cell Epitope from Tyrosinase Requires ER to Cytosol Translocation, Peptide-N-glycanase, and ERAP1 (2006)
5. Antony P.A., Piccirillo C.A., Akpinarli A., Finkelstein S.E., Speiss P.J., Surman D.R., Palmer D.C., Chan C.C., Klebanoff C.A., Overwijk W.W., Rosenberg S.A., and Restifo N.P. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174 (2005) 2591-2601
6. Bachmann M.F., Gallimore A., Linkert S., Cerundolo V., Lanzavecchia A., Kopf M., and Viola A. Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. J. Exp. Med. 189 (1999) 1521-1530
7. Bakker A.B., Schreurs M.W., Tafazzul G., de Boer A.J., Kawakami Y., Adema G.J., and Figdor C.G. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer 62 (1995) 97-102
8. Battyani Z., Xerri L., Hassoun J., Bonerandi J.J., and Grob J.J. Tyrosinase gene expression in human tissues. Pigment Cell Res. 6 (1993) 400-405
9. Brystryn J.-C., Rigel D., Friedman R.J., and Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch. Dermatol. 123 (1987) 1053-1055
10. + T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J. Immunol. 167 (2001) 5824-5831
11. Bullock T.N., Mullins D.W., and Engelhard V.H. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J. Immunol. 170 (2003) 1822-1829
12. Bullock T.N.J., Colella T.A., and Engelhard V.H. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J. Immunol. 164 (2000) 2354-2361
13. Bullock T.N.J., and Engelhard V.H. Differential avidity maturation after immunization of self-tolerant mice (2006)
14. Cawthon A.G., Lu H., and Alexander-Miller M.A. Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: Correlation with CD8ab versus CD8aa expression. J. Immunol. 167 (2001) 2577-2584
15. Celis E., Tsai V., Crimi C., DeMars R., Wentworth P.A., Chesnut R.W., Grey H.M., Sette A., and Serra H.M. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91 (1994) 2105-2109
16. Chaux P., Luiten R., Demotte N., Vantomme V., Stroobant V., Traversari C., Russo V., Schultz E., Cornelis G.R., Boon T., and van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J. Immunol. 163 (1999) 2928-2936
17. Chaux P., Vantomme V., Stroobant V., Thielemans K., Corthals J., Luiten R., Eggermont A.M.M., Boon T., and van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes. J. Exp. Med. 189 (1999) 767-777
18. Chianese-Bullock K.A., Pressley J., Garbee C., Hibbitts S., Murphy C., Yamshchikov G., Petroni G.R., Bissonette E.A., Neese P.Y., Grosh W.W., Merrill P., Fink R., Woodson E.M., Wiernasz C.J., Patterson J.W., and Slingluff Jr. C.L. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J. Immunol. 174 (2005) 3080-3086
19. Chianese-Bullock K.A., Woodson E.M., Tao H., Boerner S.A., Smolkin M., Grosh W.W., Neese P.Y., Merrill P., Petroni G.R., and Slingluff Jr. C.L. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J. Immunother. 28 (2005) 412-419
20. Colella T.A., Bullock T.N.J., Russell L.B., Mullins D.W., Overwijk W., Luckey C.J., Pierce R.A., Restifo N.P., and Engelhard V.H. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy. J. Exp. Med. 191 (2000) 1221-1231
21. Cox A.L., Skipper J., Chen Y., Henderson R.A., Darrow T.L., Shabanowitz J., Engelhard V.H., Hunt D.F., and Slingluff Jr. C.L. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264 (1994) 716-719
22. Cragun W.C., Yamshchikov G.V., Bissonette E.A., Smolkin M.E., Eastham S., Petroni G.R., Schrecengost R.S., Woodson E.M., and Slingluff Jr. C.L. Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients. Cancer Immunol. Immunother. 54 (2005) 1095-1105
23. Curtsinger J.M., Lins D.C., and Mescher M.F. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to TCR/CD8 signaling in response to antigen. J. Immunol. 160 (1998) 3236-3243
24. Daniels G.A., Sanchez-Perez L., Diaz R.M., Kottke T., Thompson J., Lai M., Gough M., Karim M., Bushell A., Chong H., Melcher A., Harrington K., and Vile R.G. A simple method to cure established tumors by inflammatory killing of normal cells. Nat. Biotechnol. 22 (2004) 1125-1132
25. Das P.K., van den Wijngaard R.M., Wankowicz-Kalinska A., and Le Poole I.C. A symbiotic concept of autoimmunity and tumour immunity: Lessons from vitiligo. Trends Immunol. 22 (2001) 130-136
26. Derbinski J., Schulte A., Kyewski B., and Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat. Immunol. 2 (2001) 1032-1039
27. Derby M.A., Alexander-Miller M.A., Tse R., and Berzofsky J.A. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166 (2001) 1690-1697
28. Dunbar P.R., Chen J.L., Chao D., Rust N., Teisserenc H., Ogg G.S., Romero P., Weynants P., and Cerundolo V. Cutting edge: Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J. Immunol. 162 (1999) 6959-6962
29. Eggert A.A., Schreurs M.W., Boerman O.C., Oyen W.J., de Boer A.J., Punt C.J., Figdor C.G., and Adema G.J. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 59 (1999) 3340-3345
30. Ehl S., Hombach J., Aichele P., Rulicke T., Odermatt B., Hengarter H., Zinkernagel R., and Pircher H. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells. J. Exp. Med. 187 (1998) 763-774
31. Engelhard V.H., Bullock T.N., Colella T.A., and Mullins D.W. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use. Cancer J. Sci. Am. 6 Suppl. 3 (2000) S272-S280
32. Engelhard V.H., Bullock T.N., Colella T.A., Sheasley S.L., and Mullins D.W. Antigens derived from melanocyte differentiation proteins: Self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev. 188 (2002) 136-146
33. Engelhard V.H., Lacy E., and Ridge J.P. Influenza A specific, HLA-A2.1 restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein. J. Immunol. 146 (1991) 1226-1232
34. Ferris R.L., Hall C., Sipsas N.V., Safrit J.T., Trocha A., Koup R.A., Johnson R.P., and Siliciano R.F. Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: Dependence on TAP1/2 and mechanisms for cytosolic localization. J. Immunol. 162 (1999) 1324-1332
35. Ganss R., Ryschich E., Klar E., Arnold B., and Hammerling G.J. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62 (2002) 1462-1470
36. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J.J., De Plaen E., Lethe B., Brasseur F., and Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179 (1994) 921-930
37. Gimenez E., Lavado A., Giraldo P., and Montoliu L. Tyrosinase gene expression is not detected in mouse brain outside the retinal pigment epithelium cells. Eur. J. Neurosci. 18 (2003) 2673-2676
38. Goverman J. Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein. Immunol. Rev. 169 (1999) 147-159
39. Grohmann U., Bianchi R., Ayroldi E., Belladonna M.L., Surace D., Fioretti M.C., and Puccetti P. A tumor-associated and self-antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can preent or revert the anergic state. J. Immunol. 158 (1997) 3593-3602
40. Halder T., Pawelec G., Kirkin A.F., Zeuthen J., Meyer H.E., Kun L., and Kalbacher H. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res. 57 (1997) 3238-3244
41. Han R., Baden H.P., Brissette J.L., and Weiner L. Redefining the skin's pigmentary system with a novel tyrosinase assay. Pigment Cell Res. 15 (2002) 290-297
42. + T cells in the face of tumor cell metastasis to draining lymph nodes (2006)
43. Hemmer B., Stefanova I., Vergelli M., Germain R.N., and Martin R. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J. Immunol. 160 (1998) 5807-5814
44. Hemmi H., Yoshino M., Yamazaki H., Naito M., Iyoda T., Omatsu Y., Shimoyama S., Letterio J.J., Nakabayashi T., Tagaya H., Yamane T., Ogawa M., et al. Skin antigens in the steady state are trafficked to regional lymph nodes by transforming growth factor-beta1-dependent cells. Int. Immunol. 13 (2001) 695-704
45. Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J., Hunt D.F., Engelhard V.H., Ross M.M., and Slingluff Jr. C.L. Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma. Cancer Res. 64 (2004) 1157-1163
46. Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J., Hunt D.F., Engelhard V.H., Slingluff Jr. C.L., and Ross M.M. Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes. Immunol. Lett. 90 (2003) 131-135
47. Hogan K.T., Sutton J.N., Chu K.U., Busby J.A., Shabanowitz J., Hunt D.F., and Slingluff Jr. C.L. Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Cancer Immunol. Immunother. 54 (2005) 359-371
48. Huang L.Q., Brasseur F., Serrano A., De Plaen E., van der Bruggen P., Boon T., and Van Pel A. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J. Immunol. 162 (1999) 6849-6854
49. Jaeger E., Bernhard H., Romero P., Ringhoffer M., Arand M., Karbach J., Ilsemann C., Hagedorn M., and Knuth A. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66 (1996) 162-169
50. Jager D., Jager E., and Knuth A. Vaccination for malignant melanoma: Recent developments. Oncology 60 (2001) 1-7
51. Jager E., Maeurer M., Hohn H., Karbach J., Jager D., Zidianakis Z., Bakhshandeh-Bath A., Orth J., Neukirch C., Necker A., Reichert T.E., and Knuth A. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int. J. Cancer 86 (2000) 538-547
52. Jonuleit H., Giesecke-Tuettenberg A., Tuting T., Thurner-Schuler B., Stuge T.B., Paragnik L., Kandemir A., Lee P.P., Schuler G., Knop J., and Enk A.H. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93 (2001) 243-251
53. Kaech S.M., Wherry E.J., and Ahmed R. Effector and memory T-cell differentiation: Implications for vaccine development. Nature Rev. Immunol. 2 (2002) 251-262
54. Kahn M., Sugawara H., McGowan P., Okuno K., Nagoya S., Hellstrom K.E., and Greenberg P. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J. Immunol. 146 (1991) 3235-3241
55. Kawakami Y., Eliyahu S., Jennings C., Sakaguchi K., Kang X., Southwood S., Robbins P.F., Sette A., Appella E., and Rosenberg S.A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154 (1995) 3961-3968
56. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R., Appella E., and Rosenberg S.A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180 (1994) 347-352
57. Kawakami Y., Robbins P.F., Wang X., Tupesis J.P., Parkhurst M.R., Kang X., Sakaguchi K., Appella E., and Rosenberg S.A. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J. Immunol. 161 (1998) 6985-6992
58. Kayaga J., Souberbielle B.E., Sheikh N., Morrow W.J., Scott-Taylor T., Vile R., Chong H., and Dalgleish A.G. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther. 6 (1999) 1475-1481
59. Kierstead L.S., Ranieri E., Olson W., Brusic V., Sidney J., Sette A., Kasamon Y.L., Slingluff C.L.J., Kirkwood J.M., and Storkus W.J. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+ T cells. Br. J. Cancer 85 (2001) 1738-1745
60. Kirkwood J.M., Ibrahim J.G., Sondak V.K., Richards J., Flaherty L.E., Ernstoff M.S., Smith T.J., Rao U., Steele M., and Blum R.H. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18 (2000) 2444-2458
61. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., and Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 (see comments). J. Clin. Oncol. 14 (1996) 7-17
62. Kittlesen D.J., Thompson L.W., Gulden P.H., Skipper J.C., Colella T.A., Shabanowitz J.A., Hunt D.F., Engelhard V.H., and Slingluff Jr. C.L. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development. J. Immunol. 160 (1998) 2099-2106
63. Knutson K.L., Schiffman K., and Disis M.L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107 (2001) 477-484
64. Kobayashi H., Kokubo T., Sato K., Kimura S., Asano K., Takahashi H., Iizuka H., Miyokawa N., and Katagiri M. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res. 58 (1998) 296-301
65. Kraal G., Schornagel K., Streeter P.R., Holzmann B., and Butcher E.C. Expression of the mucosal vascular addressin, MAdCAM-1, on sinus-lining cells in the spleen. Am. J Pathol. 147 (1995) 763-771
66. Kunisada T., Lu S.Z., Yoshida H., Nishikawa S., Nishikawa S., Mizoguchi M., Hayashi S., Tyrrell L., Williams D.A., Wang X., and Longley B.J. Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J. Exp. Med. 187 (1998) 1565-1573
67. + T Cells. J. Exp. Med. 186 (1997) 239-245
68. Kurts C., Sutherland R.M., Davey G., Li M., Lew A.M., Blanas E., Carbone F.R., Miller J.F., and Heath W.R. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA 96 (1999) 12703-12707
69. Lappin M.B., Weiss J.M., Delattre V., Mai B., Dittmar H., Maier C., Manke K., Grabbe S., Martin S., and Simon J.C. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 98 (1999) 181-188
70. Li K., Adibzadeh M., Halder T., Kalbacher H., Heinzel S., Muller C., Zeuthen J., and Pawelec G. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol. Immunother. 47 (1998) 32-38
71. Limmer A., Ohl J., Kurts C., Ljunggren H.G., Reiss Y., Groettrup M., Momburg F., Arnold B., and Knolle P.A. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat. Med. 6 (2000) 1348-1354
72. Limmer A., Sacher T., Alferink J., Kretschmar M., Schonrich G., Nichterlein T., Arnold B., and Hammerling G.J. Failure to induce organ-specific autoimmunity by breaking of tolerance: Importance of the microenvironment. Eur. J. Immunol. 28 (1998) 2395-2406
73. Man S., Newberg M.H., Crotzer V.L., Luckey C.J., Williams N.S., Chen Y., Huczko E.L., Ridge J.P., and Engelhard V.H. Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. Int. Immunol. 7 (1995) 597-605
74. Manici S., Sturniolo T., Imro M.A., Hammer J., Sinigaglia F., Noppen C., Spagnoli G., Mazzi B., Bellone M., Dellabona P., and Protti M.P. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189 (1999) 871-876
75. Marchand M., Weynants P., Rankin E., Arienti F., Belli F., Parmiani G., Cascinelli N., Bourlond A., Vanwijck R., Humblet Y., Canon J.L., Laurent C., et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63 (1995) 883-885
76. Martín-Fontecha A., Sebastiani S., Hopken U.E., Uguccioni M., Lipp M., Lanzavecchia A., and Sallusto F. Regulation of dendritic cell migration to the draining lymph node: Impact on T lymphocyte traffic and priming. J. Exp. Med. 198 (2003) 615-621
77. Mayerova D., Parke E.A., Bursch L.S., Odumade O.A., and Hogquist K.A. Langerhans cells activate naive self-antigen-specific CD8 T cells in the steady state. Immunity 21 (2004) 391-400
78. Meadows L.R., Wang W., den Haan J.M., Blokland E., Reinhardus C., Drijfhout J.W., Shabanowitz J., Pierce R., Agulnik A., Bishop C.E., Hunt D.F., Goulmy E., and Engelhard V.H. The HLA-A*0201-restricted HY antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6 (1997) 273-281
79. Meidenbauer N., Marienhagen J., Laumer M., Vogl S., Heymann J., Andreesen R., and Mackensen A. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 170 (2003) 2161-2169
80. Mellor A.L., and Munn D.H. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. [Review, 151 refs]. Nat. Rev. Immunol. 4 (2004) 762-774
81. Merad M., Hoffmann P., Ranheim E., Slaymaker S., Manz M.G., Lira S.A., Charo I., Cook D.N., Weissman I.L., Strober S., and Engleman E.G. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat. Med. 10 (2004) 510-517
82. Merad M., Manz M.G., Karsunky H., Wagers A., Peters W., Charo I., Weissman I.L., Cyster J.G., and Engleman E.G. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat. Immunol. 3 (2002) 1135-1141
83. Mora J.R., Cheng G., Picarella D., Briskin M., Buchanan N., and von Andrian U.H. Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J. Exp. Med. 201 (2005) 303-316
84. Morgan D.J., Kreuwel H.T., and Sherman L.A. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J. Immunol. 163 (1999) 723-727
85. Morse M.A., Coleman R.E., Akabani G., Niehaus N., Coleman D., and Lyerly H.K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59 (1999) 56-58
86. Mosse C.A., Hsu W., and Engelhard V.H. Tyrosinase degradation via two pathways during reverse translocation to the cytosol. Biochem. Biophys. Res. Commun. 285 (2001) 313-319
87. Mullins D.W., Bullock T.N., Colella T.A., Robila V.V., and Engelhard V.H. Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201- transgenic mice. J. Immunol. 167 (2001) 4853-4860
88. Mullins D.W., and Engelhard V.H. Limited infiltration of exogenous dendritic cells and naïve T cells restricts immune responses in peripheral lymph nodes (2006)
89. Mullins D.W., and Engelhard V.H. The immunogenicity of exogenous dendritic cells differs in lymph nodes and spleen (2006)
90. Mullins D.W., Sheasley S.L., Ream R.M., Bullock T.N., Fu Y.X., and Engelhard V.H. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 198 (2003) 1023-1034
91. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., and Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4 (1998) 328-332
92. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., and Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4 (1998) 328-332
93. Newberg M.H., Smith D.H., Haertel S.B., Vining D.R., Lacy E., and Engelhard V.H. Importance of MHC class I a2 and a3 domains in the recognition of self and non-self MHC molecules. J. Immunol. 156 (1996) 2473-2480
94. Nichols L.A., Colella T.A., Chen Y., and Engelhard V.H. Self-tolerance to tyrosinase, an antigen expressed in melanocytes and melanoma is via deletion mediated by a radioresistant antigen presenting cell in the periphery (2006)
95. Nolte M.A., Hamann A., Kraal G., and Mebius R.E. The strict regulation of lymphocyte migration to splenic white pulp does not involve common homing receptors. Immunology 106 (2002) 299-307
96. Nordlund J.J., Kirkwood J.M., Forget B.M., Milton G., Albert D.M., and Lerner A.B. Vitiligo in patients with metastatic melanoma: A good prognostic sign. J. Am. Acad. Dermatol. 9 (1983) 689-696
97. Novellino L., Castelli C., and Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54 (2005) 187-207 [Review, 220 refs].
98. Ohlen C., Kalos M., Cheng L.E., Shur A.C., Hong D.J., Carson B.D., Kokot N.C., Lerner C.G., Sather B.D., Huseby E.S., and Greenberg P.D. CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J. Exp. Med. 195 (2002) 1407-1418
99. Ohlen C., Kalos M., Hong D.J., Shur A.C., and Greenberg P.D. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J. Immunol. 166 (2001) 2863-2870
100. Okada N., Tsujino M., Hagiwara Y., Tada A., Tamura Y., Mori K., Saito T., Nakagawa S., Mayumi T., Fujita T., and Yamamoto A. Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br. J. Cancer 84 (2001) 1564-1570
101. Overwijk W.W., Lee D.S., Surman D.R., Irvine K.R., Touloukian C.E., Chan C.C., Carroll M.W., Moss R., Rosenberg S.A., and Restifo N.P. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes. Proc. Natl. Acad. Sci. USA 96 (1999) 2982-2987
102. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., Dellemijn T.A., Antony P.A., Spiess P.J., Palmer D.C., Heimann D.M., Klebanoff C.A., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198 (2003) 569-580
103. Palermo B., Campanelli R., Garbelli S., Mantovani S., Lantelme E., Brazzelli V., Ardigo M., Borroni G., Martinetti M., Badulli C., Necker A., and Giachino C. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo. J. Invest. Dermatol. 117 (2001) 326-332
104. Panelli M.C., Wunderlich J., Jeffries J., Wang E., Mixon A., Rosenberg S.A., and Marincola F.M. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother. 23 (2000) 487-498
105. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10 (1998) 588-594
106. Pass H.A., Schwarz S.L., Wunderlich J.R., and Rosenberg S.A. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay (see comments). Cancer J. Sci. Am. 4 (1998) 316-323
107. Phan G.Q., Touloukian C.E., Yang J.C., Restifo N.P., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Seipp C.A., Freezer L.J., Morton K.E., Mavroukakis S.A., et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J. Immunother. 26 (2003) 349-356
108. Pierce R.A., Field E.D., den Haan J.M., Caldwell J.A., White F.M., Marto J.A., Wang W., Frost L.M., Blokland E., Reinhardus C., Shabanowitz J., Hunt D.F., et al. Cutting edge: The HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J. Immunol. 163 (1999) 6360-6364
109. Pihlgren M., Dubois P.M., Tomkowiak M., Sjogren T., and Marvel J. Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro. J. Exp. Med. 184 (1996) 2141-2151
110. Porter S.D., Hu J., and Gilks C.B. Distal upstream tyrosinase S/MAR-containing sequence has regulatory properties specific to subsets of melanocytes. Dev. Genet. 25 (1999) 40-48
111. Quarmby S., Hunter R.D., and Kumar S. Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. Anticancer Res. 20 (2000) 3375-3381
112. Quarmby S., Kumar P., and Kumar S. Radiation-induced normal tissue injury: Role of adhesion molecules in leukocyte-endothelial cell interactions. Int. J. Cancer 82 (1999) 385-395
113. Rennert P.D., Hochman P.S., Flavell R.A., Chaplin D.D., Jayaraman S., Browning J.L., and Fu Y.X. Essential role of lymph nodes in contact hypersensitivity revealed in lymphotoxin-alpha-deficient mice. J. Exp. Med. 193 (2001) 1227-1238
114. Riker A., Cormier J., Panelli M., Kammula U., Wang E., Abati A., Fetsch P., Lee K.H., Steinberg S., Rosenberg S., and Marincola F. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126 (1999) 112-120
115. Rinchik E.M., Stoye J.P., Frankel W.N., Coffin J., Kwon B.S., and Russell L.B. Molecular analysis of viable spontaneous and radiation-induced albino (c)-locus mutations in the mouse. Mut. Res. 286 (1993) 199-207
116. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., and Seipp C.A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319 (1988) 1676-1680
117. Rosenberg S.A., and White D.E. Vitiligo in patients with melanoma-normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Biol. 19 (1996) 81-84
118. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4 (1998) 321-327
119. Rott L.S., Briskin M.J., Andrew D.P., Berg E.L., and Butcher E.C. A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with beta 7 integrins and memory differentiation. J. Immunol. 156 (1996) 3727-3736
120. Scheibenbogen C., Schadendorf D., Bechrakis N.E., Nagorsen D., Hofmann U., Servetopoulou F., Letsch A., Philipp A., Foerster M.H., Schmittel A., Thiel E., and Keilholz U. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int. J. Cancer 104 (2003) 188-194
121. Scheibenbogen C., Schmittel A., Keilholz U., Allgauer T., Hofmann U., Max R., Thiel E., and Schadendorf D. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. 23 (2000) 275-281
122. Selby M., Erickson A., Dong C., Cooper S., Parham P., Houghton M., and Walker C.M. Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. J. Immunol. 162 (1999) 669-676
123. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., and Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
124. Sheasley-O'Neill S.L., Dispenza M.C., Brinkmann V., and Engelhard V.H. CD8 T cell homing receptor expression and localization to lymphoid and non-lymphoid tissues depends upon the compartment in which activation by exogenous DC occurs (2006)
125. Shirai M., Arichi T., Nishioka M., Nomura T., Ikeda K., Kawanishi K., Engelhard V.H., Feinstone S.M., and Berzofsky J.A. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 154 (1995) 2733-2742
126. Skipper J.C., Gulden P.H., Hendrickson R.C., Harthun N., Caldwell J.A., Shabanowitz J., Engelhard V.H., Hunt D.F., and Slingluff Jr. C.L. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer 82 (1999) 669-677
127. Skipper J.C., Hendrickson R.C., Gulden P.H., Brichard V., Van Pel A., Chen Y., Shabanowitz J., Wolfel T., Slingluff C.L.J., Boon T., Hunt D.F., and Engelhard V.H. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183 (1996) 527-534
128. Skipper J.C., Kittlesen D.J., Hendrickson R.C., Deacon D.D., Harthun N.L., Wagner S.N., Hunt D.F., Engelhard V.H., and Slingluff Jr. C.L. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J. Immunol. 157 (1996) 5027-5033
129. Slingluff C.L., Petroni G., Bullock K.A., Bissonette E., Hibbitts S., Murphy C., Anderson N., Grosh W.W., Neese P.Y., and Fink R. Immunological results of a phase II randomized trial of multipeptide vaccines for melanoma, pp. abstract number 7503 (2004)
130. Slingluff Jr. C.L., Petroni G.R., Yamshchikov G.V., Barnd D.L., Eastham S., Galavotti H., Patterson J.W., Deacon D.H., Hibbitts S., Teates D., Neese P.Y., Grosh W.W., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells (see comment). J. Clin. Oncol. 21 (2003) 4016-4026
131. Slingluff C.L.J., Cox A.L., Henderson R.A., Hunt D.F., and Engelhard V.H. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J. Immunol. 150 (1993) 2955-2963
132. Slingluff C.L.J., Darrow T., Vervaert C., Quinn-Allen M.A., and Seigler H.F. Human cytotoxic T cells specific for autologous melanoma cells: Successful generation from lymph node cells in seven consecutive cases. J. Natl. Cancer Inst. 80 (1988) 1016-1026
133. Slingluff C.L.J., Darrow T.L., and Seigler H.F. Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy (see comments). Ann. Surg. 210 (1989) 194-202
134. Slingluff C.L.J., Yamshchikov G., Neese P., Galavotti H., Eastham S., Engelhard V.H., Kittlesen D., Deacon D., Hibbitts S., Grosh W.W., Petroni G., Cohen R., et al. Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin. Cancer Res. 7 (2001) 3012-3024
135. Slominski A., Paus R., Plonka P., Chakraborty A., Maurer M., Pruski D., and Lukiewicz S. Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle. J. Invest Dermatol. 102 (1994) 862-869
136. Steitz J., Bruck J., Lenz J., Buchs S., and Tuting T. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: Implications for the pathophysiology of vitiligo. J. Invest Dermatol. 124 (2005) 144-150
137. Steitz J., Bruck J., Steinbrink K., Enk A., Knop J., and Tuting T. Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma. Int. J. Cancer 86 (2000) 89-94
138. Tanchot C., Guillaume S., Delon J., Bourgeois C., Franzke A., Sarukhan A., Trautmann A., and Rocha B. Modifications of CD8+ T cell function during in vivo memory or tolerance induction. Immunity 8 (1998) 581-590
139. Tatsumi T., Kierstead L.S., Ranieri E., Gesualdo L., Schena F.P., Finke J.H., Bukowski R.M., Mueller-Berghaus J., Kirkwood J.M., Kwok W.W., and Storkus W.J. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J. Exp. Med. 196 (2002) 619-628
140. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von Den Driesch P., Brocker E.B., Steinman R.M., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190 (1999) 1669-1678
141. Tief K., Hahne M., Schmidt A., and Beerman F. Tyrosinase, the key enzyme in melanin synthesis, is expressed in murine brain. Eur. J. Biochem. 241 (1996) 12-16
142. Toes R.E., Blom R.J., Offringa R., Kast W.M., and Melief C.J. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156 (1996) 3911-3918
143. Toes R.E., van der Voort E.I., Schoenberger S.P., Drijfhout J.W., van Bloois L., Storm G., Kast W.M., Offringa R., and Melief C.J. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160 (1998) 4449-4456
144. Topalian S.L., Gonzales M.I., Parkhurst M., Li Y.F., Southwood S., Sette A., Rosenberg S.A., and Robbins P.F. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183 (1996) 1965-1971
145. Traversari C., van der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., and Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176 (1992) 1453-1457
146. van Elsas A., Hurwitz A.A., and Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. Proc. Natl. Acad. Sci. USA 96 (1999) 2982
147. Vezys V., Olson S., and Lefrancois L. Expression of intestine-specific antigen reveals novel pathways of CD8 T cell tolerance induction. Immunity 12 (2000) 505-514
148. Vitiello A., Marchesini D., Furze J., Sherman L.A., and Chestnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173 (1991) 1007-1015
149. Wang R.F., Johnston S.L., Zeng G., Topalian S.L., Schwartzentruber D.J., and Rosenberg S.A. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161 (1998) 3598-3606
150. Weber J.S., Hua F.L., Spears L., Marty V., Kuniyoshi C., and Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother. 22 (1999) 431-440
151. Wentworth P.A., Sette A., Celis E., Sidney J., Southwood S., Crimi C., Stitely S., Keogh E., Wong N.C., Livingston B., Alazard D., Vitiello A., et al. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int. Immunol. 8 (1996) 651-659
152. Wentworth P.A., Vitiello A., Sidney J., Keogh E., Chesnut R.W., Grey H., and Sette A. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. 26 (1996) 97-101
153. Wong R., Lau R., Chang J., Kuus-Reichel T., Brichard V., Bruck C., and Weber J. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Clin. Cancer Res. 10 (2004) 5004-5013
154. Woodson E.M., Chianese-Bullock K.A., Wiernasz C.J., Bissonette E.A., Grosh W.W., Neese P.Y., Merrill P.K., Barnd D.L., Petroni G.R., and Slingluff Jr. C.L. Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine. J. Immunother. 27 (2004) 380-388
155. Yamshchikov G.V., Barnd D.L., Eastham S., Galavotti H., Patterson J.W., Deacon D.H., Teates D., Neese P., Grosh W.W., Petroni G.R., Engelhard V.H., and Slingluff Jr. C.L. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and blood of melanoma patients. Int. J. Cancer 92 (2001) 703-711
156. Yamshchikov G.V., Mullins D.W., Chang C.C., Ogino T., Thompson L., Pressley J., Galavotti H., Aquila W., Deacon D., Ross W.G., Patterson J.W., Engelhard V.H., et al. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J. Immunol. 174 (2005) 6863-6871
157. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., and Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192 (2000) 1637-1644
158. Zarling A.L., Ficarro S.B., White F.M., Shabanowitz J., Hunt D.F., and Engelhard V.H. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J. Exp. Med. 192 (2000) 1755-1762
159. Zarling A.L., Polefrone J.M., Hopkins L.M., Evans A.M., Shabanowitz J., Lewis S.T., Hunt D.F., and Engelhard V.H. Phosphoproteomic evaluation of the class I MHC peptide repertoire on cancer cells (2006)
160. Zarour H.M., Kirkwood J.M., Kierstead L.S., Herr W., Brusic V., Slingluff C.L.J., Sidney J., Sette A., and Storkus W.J. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc. Natl. Acad. Sci. USA 97 (2000) 400-405
161. Zeh III H.J., Perry-Lalley D., Dudley M.E., Rosenberg S.A., and Yang J.C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162 (1999) 989-994
162. Zhao X., Deak E., Soderberg K., Linehan M., Spezzano D., Zhu J., Knipe D.M., and Iwasaki A. Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J. Exp. Med. 197 (2003) 153-162